Oncolytic virotherapy has evolved from a tumor-selective cytolytic strategy into a programmable immunotherapeutic platform that reshapes the tumor microenvironment (TME). Oncolytic viruses (OVs) selectively infect malignant cells, induce immunogenic cell death, release tumor antigens, and activate innate and adaptive i...
A. Atoom, J. Rizaev, D. Polatova et al.· Cancer Treatment and Researc...· 0 citations
The immunosuppressive stroma in colorectal cancer (CRC) plays a central role in therapeutic resistance. Modulating key targets within this stromal compartment has been proposed as a promising strategy for restoring antitumor immunity and overcoming resistance mechanisms. Several immunomodulatory agents, including next-...
Qamar Abuhassan, Usamah Sayed, Pareshkumar N. Patel et al.· Advanced Pharmaceutical Bull...· 0 citations
The blood-brain barrier (BBB) is critical in CNS pharmacotherapy; it blocks the entry of 98 per cent of small-molecule compounds and almost all macromolecules into the brain parenchyma via tight junction complexes, efflux transporter action, and enzymatic breakdown. This review focuses on the mechanistic basis of BBB r...
Manish R. Bhise, K. Thejomoorthy, Mohit Kumar et al.· Current Drug Delivery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.